LIVTENCITY (maribavir)
ANTIVIRAL - CMV INFECTION·POST-TRANSPLANT CYTOMEGALOVIRUS INFECTION
Takeda Pharmaceuticals America
Indication
Post-transplant cytomegalovirus infection
Post-transplant cytomegalovirus infection is an opportunistic viral complication that develops in solid organ or hematopoietic stem cell transplant recipients due to impaired cell-mediated immunity. Read more about Post-transplant cytomegalovirus infection
1 drugs 1 manufacturers
Drugs that treat it
Common Post-transplant cytomegalovirus infection therapies.
Filter & compare in the drug finder →Opens the drug finder with Post-transplant cytomegalovirus infection preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPost-transplant cytomegalovirus infection is an opportunistic viral complication that develops in solid organ or hematopoietic stem cell transplant recipients due to impaired cell-mediated immunity.
Pathophysiologically, it arises from primary infection via a seropositive donor, superinfection, or reactivation of latent human betaherpesvirus 5 residing in host tissues.
The infection is characterized by active viral replication evidenced by detectable cytomegalovirus DNAemia or antigenemia in bodily fluids or tissues.
Clinically, it ranges from asymptomatic viral replication to symptomatic cytomegalovirus syndrome—marked by persistent fever, malaise, and cytopenias—or progresses to invasive end-organ disease such as pneumonitis, gastrointestinal ulceration, hepatitis, and allograft rejection.
- nih.gov
Post-transplant cytomegalovirus infection is an opportunistic viral complication that develops in solid organ or hematopoietic stem cell transplant recipients due to impaired cell-mediated immunity Pathophysiologically, it arises from primary infection via a seropositive donor, superinfection, or reactivation of latent human betaherpesvirus 5 residing in host tissues The infection is characterized by active viral replication evidenced by detectable cytomegalovirus DNAemia or antigenemia in bodil...
- nih.gov
Post-transplant cytomegalovirus infection is an opportunistic viral complication that develops in solid organ or hematopoietic stem cell transplant recipients due to impaired cell-mediated immunity
- nih.gov
Post-transplant cytomegalovirus infection is an opportunistic viral complication that develops in solid organ or hematopoietic stem cell transplant recipients due to impaired cell-mediated immunity
- nih.gov
Pathophysiologically, it arises from primary infection via a seropositive donor, superinfection, or reactivation of latent human betaherpesvirus 5 residing in host tissues
- fda.gov
The infection is characterized by active viral replication evidenced by detectable cytomegalovirus DNAemia or antigenemia in bodily fluids or tissues Clinically, it ranges from asymptomatic viral replication to symptomatic cytomegalovirus syndrome—marked by persistent fever, malaise, and cytopenias—or progresses to invasive end-organ disease such as pneumonitis, gastrointestinal ulceration, hepatitis, and allograft rejection
- nih.gov
Clinically, it ranges from asymptomatic viral replication to symptomatic cytomegalovirus syndrome—marked by persistent fever, malaise, and cytopenias—or progresses to invasive end-organ disease such as pneumonitis, gastrointestinal ulceration, hepatitis, and allograft rejection
Personalize your experience
Follow Post-transplant cytomegalovirus infection and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.